Differentiation-dependent susceptibility of human muscle cells to Zika virus infection.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
08 2020
Historique:
received: 31 05 2019
accepted: 09 04 2020
revised: 22 09 2020
pubmed: 21 8 2020
medline: 8 10 2020
entrez: 21 8 2020
Statut: epublish

Résumé

Muscle cells are potential targets of many arboviruses, such as Ross River, Dengue, Sindbis, and chikungunya viruses, that may be involved in the physiopathological course of the infection. During the recent outbreak of Zika virus (ZIKV), myalgia was one of the most frequently reported symptoms. We investigated the susceptibility of human muscle cells to ZIKV infection. Using an in vitro model of human primary myoblasts that can be differentiated into myotubes, we found that myoblasts can be productively infected by ZIKV. In contrast, myotubes were shown to be resistant to ZIKV infection, suggesting a differentiation-dependent susceptibility. Infection was accompanied by a caspase-independent cytopathic effect, associated with paraptosis-like cytoplasmic vacuolization. Proteomic profiling was performed 24h and 48h post-infection in cells infected with two different isolates. Proteome changes indicate that ZIKV infection induces an upregulation of proteins involved in the activation of the Interferon type I pathway, and a downregulation of protein synthesis. This work constitutes the first observation of primary human muscle cells susceptibility to ZIKV infection, and differentiation-dependent restriction of infection from myoblasts to myotubes. Since myoblasts constitute the reservoir of stem cells involved in reparation/regeneration in muscle tissue, the infection of muscle cells and the viral-induced alterations observed here could have consequences in ZIKV infection pathogenesis.

Identifiants

pubmed: 32817655
doi: 10.1371/journal.pntd.0008282
pii: PNTD-D-19-00850
pmc: PMC7508361
doi:

Substances chimiques

Interferon Type I 0
Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0008282

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Neurovirol. 2018 Feb;24(1):52-61
pubmed: 29063515
Pediatr Infect Dis J. 2010 Mar;29(3):238-42
pubmed: 20032806
J Neurol Sci. 2011 Jan 15;300(1-2):14-8
pubmed: 21081241
Cell Death Differ. 2004 Oct;11(10):1066-75
pubmed: 15195070
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
EMBO J. 2017 Jun 14;36(12):1653-1668
pubmed: 28473450
Euro Surveill. 2014 Mar 06;19(9):
pubmed: 24626205
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14376-81
pubmed: 11121041
Trends Microbiol. 2015 Jan;23(1):35-43
pubmed: 25449049
Ann Intern Med. 2017 Jan 17;166(2):99-108
pubmed: 27893080
Case Rep Rheumatol. 2016;2016:5395249
pubmed: 27119037
Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20
pubmed: 12995440
J Clin Diagn Res. 2016 Dec;10(12):OD05-OD06
pubmed: 28208912
MMWR Morb Mortal Wkly Rep. 2016 Sep 30;65(38):1032-8
pubmed: 27684886
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
Vet Res. 2016 Jan 08;47:9
pubmed: 26743565
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Infect Genet Evol. 2017 Apr;49:134-137
pubmed: 28095299
Cell Death Dis. 2017 Oct 12;8(10):e3106
pubmed: 29022904
PLoS Pathog. 2008 Feb 8;4(2):e29
pubmed: 18282093
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941671
PLoS Pathog. 2017 Mar 9;13(3):e1006219
pubmed: 28278237
PLoS One. 2007 Jun 13;2(6):e527
pubmed: 17565380
Emerg Infect Dis. 2014 Jun;20(6):1085-6
pubmed: 24856001
Nature. 2008 Sep 11;455(7210):242-5
pubmed: 18690214
Euro Surveill. 2016 Jul 14;21(28):
pubmed: 27447300
J Infect Dis. 2012 Aug 1;206(3):407-14
pubmed: 22615321
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Aging Cell. 2007 Aug;6(4):515-23
pubmed: 17559502
Bioinformatics. 2006 Aug 15;22(16):1979-87
pubmed: 16777905
Hum Gene Ther. 1997 Aug 10;8(12):1429-38
pubmed: 9287143
J Biol Chem. 2011 Feb 18;286(7):5151-6
pubmed: 21149444
J Virol. 2015 Sep;89(17):8880-96
pubmed: 26085147
Nat Microbiol. 2018 Mar;3(3):302-309
pubmed: 29379210
Lancet. 2016 May 21;387(10033):2125-2132
pubmed: 26993883
Am J Trop Med Hyg. 2016 Jun 1;94(6):1362-1369
pubmed: 27022155
Lancet. 2016 Apr 9;387(10027):1531-1539
pubmed: 26948433
Bioinformatics. 2017 Jan 1;33(1):135-136
pubmed: 27605098
PLoS One. 2013 Nov 05;8(11):e79628
pubmed: 24223983
Cell Stem Cell. 2016 May 5;18(5):587-90
pubmed: 26952870
Virol J. 2011 Sep 08;8:432
pubmed: 21902836
Lancet. 2016 Aug 27;388(10047):868
pubmed: 27597462
Proteomics. 2016 Jan;16(1):29-32
pubmed: 26572953
Virology. 2016 Jun;493:217-26
pubmed: 27060565
Cell Host Microbe. 2016 Aug 10;20(2):155-66
pubmed: 27443522
Cell Stem Cell. 2016 Nov 3;19(5):672
pubmed: 27814481
Nat Cell Biol. 2013 May;15(5):472-80
pubmed: 23604317
Southeast Asian J Trop Med Public Health. 2015;46 Suppl 1:149-52
pubmed: 26506741
J Proteome Res. 2015 Aug 7;14(8):3348-61
pubmed: 26074025
Sci Rep. 2017 Jan 23;7:40780
pubmed: 28112162
Infection. 2012 Apr;40(2):125-30
pubmed: 22005935
Cell Stem Cell. 2016 May 5;18(5):591-6
pubmed: 27038591
J Virol. 2006 Jan;80(2):737-49
pubmed: 16378976
PLoS Negl Trop Dis. 2016 Apr 19;10(4):e0004682
pubmed: 27093158
Front Neurol. 2012 Mar 21;3:37
pubmed: 22461779
Sci Rep. 2016 Feb 19;6:21406
pubmed: 26892458
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Cell Res. 2016 Jul;26(7):753-4
pubmed: 27283801
Antiviral Res. 2018 Dec;160:38-47
pubmed: 30326204
Antiviral Res. 2010 Sep;87(3):281-94
pubmed: 20452379
PLoS Negl Trop Dis. 2019 May 3;13(5):e0007375
pubmed: 31050676
J Immunol. 2000 May 15;164(10):5459-65
pubmed: 10799913
J Gen Virol. 2008 Jul;89(Pt 7):1605-1615
pubmed: 18559930
Cell Rep. 2017 Jan 10;18(2):324-333
pubmed: 28076778
Vector Borne Zoonotic Dis. 2005 Fall;5(3):252-7
pubmed: 16187894
J Gen Virol. 2017 Aug;98(8):2061-2068
pubmed: 28786784
Emerg Microbes Infect. 2016 Aug 24;5:e93
pubmed: 27553173
Brain Res Bull. 2017 Jan;128:40-47
pubmed: 27871950
MMWR Morb Mortal Wkly Rep. 2016 May 06;65(17):451-5
pubmed: 27149205

Auteurs

Vincent Legros (V)

Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de virologie, Institut Pasteur, Paris, France.
Université de Paris, Paris, France.
UMR CNRS 3569, Paris, France.

Patricia Jeannin (P)

Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de virologie, Institut Pasteur, Paris, France.
Université de Paris, Paris, France.
UMR CNRS 3569, Paris, France.

Julien Burlaud-Gaillard (J)

INSERM U1259 & Plate Forme IBiSA de Microscopie Electronique, Université François Rabelais and CHRU, Tours, France.

Thibault Chaze (T)

Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS, Institut Pasteur, Paris, France.

Quentin Giai Gianetto (QG)

Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS, Institut Pasteur, Paris, France.
Bioinformatics and Biostatistics Hub, C3BI, USR 3756 IP CNRS, Institut Pasteur, Paris, France.

Gillian Butler-Browne (G)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.

Vincent Mouly (V)

Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.

Jim Zoladek (J)

Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de virologie, Institut Pasteur, Paris, France.
Université de Paris, Paris, France.
UMR CNRS 3569, Paris, France.

Philippe V Afonso (PV)

Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de virologie, Institut Pasteur, Paris, France.
Université de Paris, Paris, France.
UMR CNRS 3569, Paris, France.

Mariela-Natacha Gonzàlez (MN)

Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Brazilian National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Rio de Janeiro, Brazil.

Mariette Matondo (M)

Proteomics Platform, Mass Spectrometry for Biology Unit, USR 2000 IP CNRS, Institut Pasteur, Paris, France.

Ingo Riederer (I)

Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Brazilian National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Rio de Janeiro, Brazil.

Philippe Roingeard (P)

INSERM U1259 & Plate Forme IBiSA de Microscopie Electronique, Université François Rabelais and CHRU, Tours, France.

Antoine Gessain (A)

Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de virologie, Institut Pasteur, Paris, France.
Université de Paris, Paris, France.
UMR CNRS 3569, Paris, France.

Valérie Choumet (V)

Unité Environnement et Risques Infectieux, Département de santé globale, Institut Pasteur, Paris, France.

Pierre-Emmanuel Ceccaldi (PE)

Unité Epidémiologie et Physiopathologie des Virus Oncogènes, Département de virologie, Institut Pasteur, Paris, France.
Université de Paris, Paris, France.
UMR CNRS 3569, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH